4523 Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6,478.00 |
| 52 Week High | JP¥9,614.00 |
| 52 Week Low | JP¥5,795.00 |
| Beta | -0.042 |
| 11 Month Change | -4.28% |
| 3 Month Change | 5.87% |
| 1 Year Change | -30.95% |
| 33 Year Change | -39.43% |
| 5 Year Change | 6.67% |
| Change since IPO | 297.77% |
Recent News & Updates
Shareholder Returns
| 4523 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.7% | 3.6% | 2.4% |
| 1Y | -31.0% | 16.4% | 24.6% |
Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned 16.4% over the past year.
Return vs Market: 4523 underperformed the JP Market which returned 24.6% over the past year.
Price Volatility
| 4523 volatility | |
|---|---|
| 4523 Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4523 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4523's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,067 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
| 4523 fundamental statistics | |
|---|---|
| Market cap | JP¥1.85t |
| Earnings (TTM) | JP¥42.41b |
| Revenue (TTM) | JP¥741.75b |
43.7x
P/E Ratio2.5x
P/S RatioIs 4523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4523 income statement (TTM) | |
|---|---|
| Revenue | JP¥741.75b |
| Cost of Revenue | JP¥155.33b |
| Gross Profit | JP¥586.42b |
| Other Expenses | JP¥544.01b |
| Earnings | JP¥42.41b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 02, 2024
| Earnings per share (EPS) | 148.35 |
| Gross Margin | 79.06% |
| Net Profit Margin | 5.72% |
| Debt/Equity Ratio | 17.7% |
How did 4523 perform over the long term?
See historical performance and comparison